GlassScriptPhysician profile
Richard Huber
NPI 1083715288
$1,943.89
in general payments reported to CMS, 2019-2025
30 companies · $646 in 2025
The $646 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $410 · 2023: $417 · 2024: $308 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $280.50 | 2022-2025 | |
| Novo Nordisk INC | $230.61 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $177.22 | 2021-2025 | |
| Pfizer INC. | $125.74 | 2023-2025 | |
| Corcept Therapeutics | $116.16 | 2023-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $110.70 | 2022-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $82.13 | 2021-2025 | |
| Esperion Therapeutics, INC. | $68.79 | 2022-2025 | Nexletol |
| Exact Sciences Corporation | $66.01 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.59 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $55.50 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $54.87 | 2022-2024 | |
| Glaxosmithkline, LLC. | $54.04 | 2021-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $46.04 | 2021-2022 | |
| Dexcom, INC. | $44.88 | 2023-2024 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $43.27 | 2021 | |
| Antares Pharma, INC. | $37.83 | 2025 | Xyosted |
| Lilly USA, LLC | $37.47 | 2023 | Mounjaro, Trulicity |
| Eisai INC. | $32.08 | 2025 | |
| Amgen INC. | $32.01 | 2023 | Repatha |
| Bausch Health US, LLC | $26.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.93 | 2022 | |
| Vanda Pharmaceuticals INC. | $24.10 | 2023 | Hetlioz |
| Averitas Pharma INC. | $20.58 | 2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $18.74 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $17.72 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $17.65 | 2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.24 | 2025 | Caplyta |
| Electromed, INC. | $13.93 | 2025 | Smartvest |
| Kowa Pharmaceuticals America, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Huber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.